Covered recipient · General Payments record
ROOZBEH SHARIF
Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$9,202.00
104 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $6,100.00 | 2 |
| Food and Beverage | $2,020.78 | 99 |
| Travel and Lodging | $1,047.22 | 2 |
| Education | $34.00 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| United Therapeutics Corporation | $6,482.81 | 13 |
| Verona Pharma, Inc. | $1,123.43 | 9 |
| GlaxoSmithKline, LLC. | $319.72 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $242.75 | 12 |
| AstraZeneca Pharmaceuticals LP | $167.32 | 8 |
| GENZYME CORPORATION | $163.61 | 13 |
| Merck Sharp & Dohme LLC | $139.84 | 6 |
| Electromed, Inc. | $126.51 | 11 |
| Actelion Pharmaceuticals US, Inc. | $103.02 | 2 |
| Philips North America LLC | $88.79 | 5 |
| Regeneron Healthcare Solutions, Inc. | $81.31 | 3 |
| Insmed, Inc. | $81.06 | 3 |
| Amgen Inc. | $34.00 | 1 |
| Baxter Healthcare | $33.27 | 1 |
| Inspire Medical Systems, Inc. | $14.56 | 1 |
Page 2 of 3; records 51–100 of 104 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ROOZBEH SHARIF
NPI 1396037008 · CMS profile ID 688165
Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease
NEDERLAND, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 104 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1396037008?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ROOZBEH SHARIF, NPI 1396037008, CMS profile ID 688165. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 104 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396037008?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). ROOZBEH SHARIF, NPI 1396037008, CMS profile ID 688165. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 104 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396037008?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- ROOZBEH SHARIF, NPI 1396037008, CMS profile ID 688165, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 104 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1396037008?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
104 matching records · $9,202.00 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 104.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $16.55 | 08/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206290663 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $20.41 | 07/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222992675 | CMS |
| Verona Pharma, Inc. | $21.83 | 07/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233756099 | CMS |
| GlaxoSmithKline, LLC. | $26.50 | 07/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191148352 | CMS |
| Electromed, Inc. | $15.49 | 07/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224593752 | CMS |
| GENZYME CORPORATION | $5.62 | 07/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233205342 | CMS |
| GlaxoSmithKline, LLC. | $19.07 | 07/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191519532 | CMS |
| Verona Pharma, Inc. | $9.58 | 07/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233756119 | CMS |
| Merck Sharp & Dohme LLC | $19.54 | 06/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238339691 | CMS |
| GlaxoSmithKline, LLC. | $14.03 | 06/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190656378 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.21 | 06/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206173074 | CMS |
| Electromed, Inc. | $21.17 | 06/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224593746 | CMS |
| Philips North America LLC | $14.82 | 06/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232605132 | CMS |
| GlaxoSmithKline, LLC. | $27.05 | 06/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191705830 | CMS |
| GENZYME CORPORATION | $15.13 | 06/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233205322 | CMS |
| GENZYME CORPORATION | $9.43 | 05/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233205324 | CMS |
| GlaxoSmithKline, LLC. | $28.96 | 05/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190759449 | CMS |
| Philips North America LLC | $19.39 | 05/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232605128 | CMS |
| Electromed, Inc. | $6.83 | 05/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224593760 | CMS |
| GlaxoSmithKline, LLC. | $15.04 | 05/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190672513 | CMS |
| Electromed, Inc. | $6.83 | 05/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224593764 | CMS |
| Merck Sharp & Dohme LLC | $27.21 | 05/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238298793 | CMS |
| Regeneron Healthcare Solutions, Inc. | $26.73 | 05/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213039521 | CMS |
| Insmed, Inc. | $27.97 | 05/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186279432 | CMS |
| GENZYME CORPORATION | $9.40 | 04/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233205314 | CMS |
| Verona Pharma, Inc. | $19.42 | 04/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233756133 | CMS |
| Merck Sharp & Dohme LLC | $28.80 | 04/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238019019 | CMS |
| United Therapeutics Corporation | $21.89 | 04/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242548832 | CMS |
| GlaxoSmithKline, LLC. | $13.63 | 04/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190521015 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $23.22 | 04/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222992673 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.86 | 04/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206783989 | CMS |
| GENZYME CORPORATION | $12.72 | 04/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233205288 | CMS |
| Regeneron Healthcare Solutions, Inc. | $38.50 | 03/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213039519 | CMS |
| GlaxoSmithKline, LLC. | $15.69 | 03/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191339338 | CMS |
| Electromed, Inc. | $11.98 | 03/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224593757 | CMS |
| United Therapeutics Corporation | $31.60 | 03/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242556658 | CMS |
| Insmed, Inc. | $28.34 | 03/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186259447 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $19.51 | 03/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222992671 | CMS |
| GENZYME CORPORATION | $22.42 | 03/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233205362 | CMS |
| United Therapeutics Corporation | $29.04 | 03/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242541642 | CMS |
| GlaxoSmithKline, LLC. | $20.63 | 02/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190621449 | CMS |
| United Therapeutics Corporation | $25.62 | 02/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242538748 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.33 | 02/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207015964 | CMS |
| Inspire Medical Systems, Inc. | $14.56 | 02/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1251508082 | CMS |
| Insmed, Inc. | $24.75 | 02/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186293997 | CMS |
| Electromed, Inc. | $6.66 | 02/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224593779 | CMS |
| Electromed, Inc. | $1.07 | 02/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224593742 | CMS |
| AstraZeneca Pharmaceuticals LP | $41.24 | 01/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206389890 | CMS |
| Actelion Pharmaceuticals US, Inc. | $74.99 | 01/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174304670 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $19.85 | 01/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222992669 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $608,346.04 | 40 |
| PY2024 | Principal investigator | $707,959.33 | 37 |
| PY2023 | Principal investigator | $63,928.74 | 10 |
| PY2022 | Principal investigator | $38,400.00 | 2 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
40 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | GENZYME CORPORATION | $1,250.00 | 12/22/2025 | Non-covered Recipient Entity Rex Tha Clinical Trials Llc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226119193 |
| Principal investigator 1 | GENZYME CORPORATION | $3,125.00 | 12/08/2025 | Non-covered Recipient Entity Rex Tha Clinical Trials Llc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226119177 |
| Principal investigator 1 | GENZYME CORPORATION | $48,850.00 | 12/08/2025 | Non-covered Recipient Entity Rex Tha Clinical Trials Llc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226119181 |
| Principal investigator 1 | GENZYME CORPORATION | $375.00 | 12/08/2025 | Non-covered Recipient Entity Rex Tha Clinical Trials Llc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226119186 |
| Principal investigator 1 | GENZYME CORPORATION | $500.00 | 12/08/2025 | Non-covered Recipient Entity Rex Tha Clinical Trials Llc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226119189 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $725.00 | 11/25/2025 | Non-covered Recipient Entity REX CLINICAL TRIALS LLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192117631 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $725.00 | 11/25/2025 | Non-covered Recipient Entity REX CLINICAL TRIALS LLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192117660 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,620.00 | 11/24/2025 | Non-covered Recipient Entity Rex Clinical Trials Llc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226097810 |
| Principal investigator 1 | GENZYME CORPORATION | $25,550.00 | 11/04/2025 | Non-covered Recipient Entity Rex Clinical Trials Llc | Evaluate how dupilumab can alter the trajectory of COPD by modifying disease progression | No dispute reported | 06/30/2026 | 1226097763 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $29,000.00 | 10/27/2025 | Non-covered Recipient Entity Rex Clinical Trials Llc | A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype | No dispute reported | 06/30/2026 | 1226097721 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,839.00 | 10/14/2025 | Non-covered Recipient Entity Rex Clinical Trials Llc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226097714 |
| Principal investigator 1 | GENZYME CORPORATION | $44,900.00 | 08/18/2025 | Non-covered Recipient Entity Rex Tha Clinical Trials Llc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226119172 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,313.00 | 08/18/2025 | Non-covered Recipient Entity Rex Clinical Trials Llc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226097636 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,700.00 | 07/21/2025 | Non-covered Recipient Entity Rex Clinical Trials Llc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226097578 |
| Principal investigator 1 | GENZYME CORPORATION | $3,400.00 | 07/14/2025 | Non-covered Recipient Entity Rex Tha Clinical Trials Llc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226119167 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,839.00 | 07/14/2025 | Non-covered Recipient Entity Rex Clinical Trials Llc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226097556 |
| Principal investigator 1 | GENZYME CORPORATION | $17,110.00 | 07/02/2025 | Non-covered Recipient Entity Rex Tha Clinical Trials Llc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226119163 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $12,000.00 | 06/23/2025 | Non-covered Recipient Entity REX CLINICAL TRIALS, LLC | A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185552381 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $12,000.00 | 06/11/2025 | Non-covered Recipient Entity REX CLINICAL TRIALS, LLC | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler | No dispute reported | 06/30/2026 | 1185552377 |
| Principal investigator 1 | ModernaTX, Inc. | $10,367.83 | 06/02/2025 | Non-covered Recipient Entity REX CLINICAL TRIALS LLC | A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age | No dispute reported | 06/30/2026 | 1252967149 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,834.00 | 05/29/2025 | Non-covered Recipient Entity Rex Clinical Trials Llc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226085485 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,826.00 | 04/23/2025 | Non-covered Recipient Entity Rex Clinical Trials Llc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226085436 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,076.40 | 04/17/2025 | Non-covered Recipient Entity REX CLINICAL TRIALS LLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192117620 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $15,000.00 | 04/09/2025 | Non-covered Recipient Entity TEXAS ARTHRITIS CENTER, PA | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185552387 |
| Principal investigator 1 | AstraZeneca UK Limited | $54,730.35 | 03/24/2025 | Non-covered Recipient Entity REX CLINICAL TRIALS, LLC | a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA | No dispute reported | 06/30/2026 | 1185552383 |
| Principal investigator 1 | ModernaTX, Inc. | $8,000.00 | 03/24/2025 | Non-covered Recipient Entity REX CLINICAL TRIALS LLC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252967151 |
| Principal investigator 1 | ModernaTX, Inc. | $2,100.00 | 03/24/2025 | Non-covered Recipient Entity REX CLINICAL TRIALS LLC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252967155 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $19,300.10 | 03/20/2025 | Non-covered Recipient Entity REX CLINICAL TRIALS LLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192117606 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,731.50 | 03/17/2025 | Non-covered Recipient Entity Rex Tha Clinical Trials Llc | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226119114 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $15,939.00 | 03/04/2025 | Non-covered Recipient Entity Rex Clinical Trials Llc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226085406 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $17,290.80 | 02/20/2025 | Non-covered Recipient Entity REX CLINICAL TRIALS LLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192117643 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,493.00 | 02/18/2025 | Non-covered Recipient Entity Rex Tha Clinical Trials Llc | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226119118 |
| Principal investigator 1 | ModernaTX, Inc. | $4,565.80 | 02/14/2025 | Non-covered Recipient Entity REX CLINICAL TRIALS LLC | A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age | No dispute reported | 06/30/2026 | 1252967153 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,562.00 | 01/30/2025 | Non-covered Recipient Entity REX CLINICAL TRIALS LLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192117613 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 01/30/2025 | Non-covered Recipient Entity REX CLINICAL TRIALS LLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192117637 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,000.00 | 01/30/2025 | Non-covered Recipient Entity REX CLINICAL TRIALS LLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192117650 |
| Principal investigator 1 | AstraZeneca UK Limited | $40,782.66 | 01/22/2025 | Non-covered Recipient Entity REX CLINICAL TRIALS, LLC | a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma | No dispute reported | 06/30/2026 | 1185552379 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,757.50 | 01/21/2025 | Non-covered Recipient Entity Rex Tha Clinical Trials Llc | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226119108 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $93,035.40 | 01/16/2025 | Non-covered Recipient Entity REX CLINICAL TRIALS LLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192111877 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $71,132.70 | 01/16/2025 | Non-covered Recipient Entity REX CLINICAL TRIALS LLC | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192117627 |